Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGFR/MET TKI
Cabozantinib
Cabometyx · Cabo
A VEGFR/MET TKI whose antiangiogenic reach brings hypertension, proteinuria and occasional nephrotic-range injury.
ModerateVEGFR/MET multikinase inhibitor · approved 2012
Renal cell carcinomaHepatocellular carcinomaMedullary thyroid cancerDifferentiated thyroid cancer (refractory)
Signature kidney injury
Hypertension
Hypertension and proteinuria are common; in pivotal RCC trials (e.g., METEOR, CABOSUN) hypertension was among the most frequent adverse events with grade >=3 rates around 15-28%. Cabozantinib is one of the TKIs most often associated with proteinuria, with case reports of nephrotic syndrome.
Source: Nervo et al., Crit Rev Oncol Hematol 2021; METEOR (Choueiri, NEJM 2015)
Mechanism of kidney injury
Inhibition of VEGFR2 signaling impairs glomerular endothelial and podocyte maintenance and reduces nitric-oxide-mediated vasodilation, producing hypertension, proteinuria and a podocytopathy (FSGS/minimal-change-like lesions); renal TMA can also occur with anti-VEGF-pathway agents. The added MET inhibition may further perturb podocyte HGF/MET survival signaling.
Clinical presentation
New or worsening hypertension with proteinuria; nephrotic-range proteinuria with edema in reported cases, and occasionally a creatinine rise.
Onset
Within weeks of starting therapy.
Reversibility
Reversible
Anticancer mechanism
Oral multikinase inhibitor of VEGFR2, MET, AXL, RET, KIT and others, simultaneously blocking angiogenesis and MET/AXL-driven tumor-cell signaling and invasion (the MET/AXL activity is thought to counter VEGFR-inhibitor escape). Used in renal cell carcinoma, hepatocellular carcinoma and medullary/differentiated thyroid cancer.
Management
Antihypertensive therapy (ACE inhibitor/ARB favored); interrupt or dose-reduce per label for grade 3 hypertension or significant proteinuria and discontinue for nephrotic syndrome, hypertensive crisis or TMA. Abnormalities typically improve with dose modification or withdrawal.
Risk factors
- Pre-existing hypertension
- Baseline proteinuria or CKD
- Diabetes
Prevention
- Baseline and periodic blood pressure and urine protein monitoring
- Blood pressure optimization before and during therapy
Note · Proteinuria signal is prominent within the TKI class (alongside lenvatinib); nephrotic presentations are case-level. Cabozantinib is also a feature in sequential-TKI proteinuria case series in thyroid cancer.
Clinical depth
Renal dose adjustment
No dose adjustment for mild-to-moderate renal impairment; cabozantinib has not been studied in severe renal impairment or ESKD, so use is cautious there. It is hepatically metabolized (CYP3A4), and dose reduction is recommended for hepatic impairment.
Dialyzability & ESKD dosing
Highly protein-bound (~99.7%) and hepatically cleared, so it is not meaningfully dialyzable; no supplemental dosing rationale for HD, and data in dialysis patients are sparse.
Differential diagnosis
TKI podocytopathy (FSGS/MCD with proteinuria + hypertension) versus anti-VEGF-antibody TMA versus baseline diabetic/hypertensive nephropathy versus prerenal AKI. The MET-inhibitor component does not change the bedside differential, which rests on biopsy pattern and temporal association.
Monitoring
- Blood pressure weekly initially, then with each visit
- Urine protein (dipstick/UPCR) before each cycle
- Serum creatinine periodically
Key trials & series
- METEOR phase III (cabozantinib vs everolimus in RCC) — hypertension a leading AE
- CABOSUN and CELESTIAL (HCC) — proteinuria/hypertension safety signals
Clinical pearls
- Cabozantinib and lenvatinib are the proteinuria heavyweights among VEGFR-TKIs.
- Its dual VEGFR/MET activity may amplify podocyte injury beyond pure VEGFR blockade.
- Sequential TKI exposure (lenvatinib then sorafenib then cabozantinib) can produce recurrent proteinuria — track urine protein across switches.
Where it strikes
Nephron segments
Glomerulus
Filtration barrier (podocytes + endothelium)
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
HypertensionGlomerular Injury / Proteinuria
Beyond the kidney
Class-level context for the major non-renal toxicities of vegfr/met tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkNephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update.Nervo A et al. · Crit Rev Oncol Hematol 2021 · PMID 34801702Identifies cabozantinib (with lenvatinib) as most often associated with proteinuria.PMIDTKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.Van Damme M et al. · Acta Clin Belg 2026 · PMID 42251484Reviews TKI proteinuria/nephrotic syndrome with a sequential lenvatinib-sorafenib-cabozantinib case.PMIDCabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.Hojer Wang L et al. · Int J Mol Sci 2023 · PMID 36768635Reviews cabozantinib treatment-related hypertension and its management.PMIDTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.Estrada CC et al. · J Am Soc Nephrol 2019 · PMID 30642877Mechanistic review of VEGFR-TKI glomerulopathy and hypertension.PMIDThe Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".Sanidas E et al. · Am J Hypertens 2018 · PMID 29788148Reviews antiangiogenic hypertension mechanisms and management.PMIDProteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.Tesarova P et al. · Folia Biol (Praha) 2013 · PMID 23537524Class review of anti-VEGF proteinuria and hypertension.
Related agents
Other agents sharing the same signature kidney injury.